近年来，乐陵市工商联紧扣高质量发展主题，持续放大商会在产业发展中的"纽带"作用，创新探 索"点、链、群"联动机制，将商会聚到"点"上、建到"链"上、扩到"群"上，为产业"链式"扩张注入了商 会动能。乐陵市工商联先后荣获全国"五好县级工商联"、全国及山东省"民营经济调查工作先进单位"等 称号，并在省产业链商会（协会）工作现场推进会上作典型发言。 延"链"建"会"，推动商会组织迭代升级 把商会建到"链"上强组织。坚持"以链聚商、以商强链"，遴选亚萨合莱国强、星光糖业、泰山体育、安 舜制药等实力雄厚、带动力强的链主企业，牵头组建产业商会，充分发挥其市场、技术与品牌优势，高 效吸纳涵盖上中下游578家会员企业，形成梯度完整、协同紧密的企业生态圈。 把平台聚到"链"上促共享。聚焦产业发展共性痛点与企业个性化需求，依托商会链接各方、聚合资源的 枢纽功能，搭建多元化、实效化共享服务平台。针对调味品等特色产业集群检验检测需求，由商会牵头 整合行业资源，高标准建设共享实验室，已为280家中小调味品企业提供便捷高效、专业权威的第三方 检测服务，帮助企业降低运营成本30%以上，有效破解中小企业 "检测难、检测贵" 问题。 把党建落 ...

近日，由中化学三化建（安徽）建设有限公司承建的淮南现代医药化工产业园一期（中试基地）项目举 行开园仪式。淮南市委副书记、市长张志强出席仪式并讲话。 自项目启动以来，面对工期紧张、任务繁重、标准严苛等多重挑战，中国化学三化建所属项目团队秉 持"开工即决战，起步即冲刺"的奋斗精神，创新管理模式，全力打造精品工程。建设过程中，项目团队 广泛应用人脸识别考勤、环境监测和视频监控等智能化手段，构建智慧工地，实现施工全过程数字化管 理；坚持每周召开生产例会，每月组织安全环保与质量专项大检查，及时排查并解决问题；夯实技术管 理基础，施工前深入开展读图讲图工作，确保参建各方准确把握设计意图与工程关键，保障图纸精准落 地。通过高标准推进项目建设，严格履行合同承诺，优质高效完成全部施工任务，彰显了一流的施工实 力和精益求精的工匠精神，为项目顺利建成作出重要贡献，赢得淮南市委市政府的高度评价。 张志强对三化建在项目建设中取得的显著成效予以充分肯定，强调淮南现代医药化工产业园一期（中试 基地）项目建设具有重大意义。他指出，必须坚持高标准、高效率的运营导向，切实做好中试基地管理 工作，着力构建覆盖研发、试验到产业化的全链条服务体系，推 ...

每经AI快讯，新和成（SZ 002001，收盘价：24.19元）12月10日晚间发布公告称，公司第九届第十六次 董事会会议于2025年12月10日以现场结合通讯表决方式召开。会议审议了《关于修订 <审计委员会年报 工作规程> 的议案》等文件。 每经头条（nbdtoutiao）——白金信用卡权益大缩水：贵宾厅限次、酒店减量⋯⋯银行吐槽没赚头，"羊 毛党"薅了个寂寞 （记者 曾健辉） 2025年1至6月份，新和成的营业收入构成为：医药化工占比90.23%，其他行业占比9.77%。 截至发稿，新和成市值为743亿元。 ...

每经头条（nbdtoutiao）——处方药变"瘾品"：国内首次报告普瑞巴林滥用致成瘾病例，网络平台暴 露"无病历可购药"漏洞，列管与否尚需科学考量 （记者 王瀚黎） 每经AI快讯，东亚药业（SH 605177，收盘价：19.4元）12月9日晚间发布公告称，公司第四届第十二次 董事会会议于2025年12月9日在浙江省台州市临海市台州湾经济技术开发区东海第五大道21号二楼会议 室五以现场结合通讯的方式召开。会议审议了《关于修订公司 <董事会审计委员会工作细则> 的议案》 等文件。 2024年1至12月份，东亚药业的营业收入构成为：医药化工占比99.19%，其他业务占比0.81%。 截至发稿，东亚药业市值为22亿元。 ...

截至发稿，新和成市值为759亿元。 每经头条（nbdtoutiao）——5年期大面积下线，3年期利率低至1.5%仍一单难求：要么"售罄"要么"额度 紧张"！中长期大额存单为何在消失？ 每经AI快讯，新和成（SZ 002001，收盘价：24.69元）12月1日晚间发布公告称，截至2025年11月30 日，公司通过股票回购专用证券账户以集中竞价交易方式回购公司股份，回购公司股份数量约为2312万 股，占公司总股本的0.7521%，最高成交价为24.45元/股，最低成交价为21.25元/股，成交总金额约为 5.19亿元。 2025年1至6月份，新和成的营业收入构成为：医药化工占比90.23%，其他行业占比9.77%。 （记者 曾健辉） ...

（编辑 任世碧） 证券日报网讯 11月28日晚间，联化科技发布公告称，2025年10月9日，公司与张立清、乐和友、董伙 祥、陈川、阮建奇和张涛签订了《股权转让合同》，决定以自有资金受让上述人员所持有的湖北郡泰医 药化工有限公司（简称"郡泰医药"）20%股权，受让总金额为2，500.00万元人民币（简称"本次受 让"）。本次股权受让完成后，公司将直接持有郡泰医药100%股权。公司按照《股权转让合同》约定， 已支付全部股权转让价款。郡泰医药已于2025年11月27日完成本次股权转让的工商变更登记手续，并取 得了荆州市市场监督管理局换发的营业执照。 ...

Core Points - *ST San Sheng reached the daily limit of 5.11 yuan, with a rise of 4.96%, and a total market value of 2.104 billion yuan on November 24, 2025 [1] - The company’s restructuring plan has been approved by the court, allowing it to avoid direct bankruptcy liquidation, with a high approval rate from creditors [2] - The introduction of strategic investor Jiheng Group will provide at least 200 million yuan in cash flow support over three years, enhancing the company's core competitiveness in the pharmaceutical sector [2] - The overall performance of the ST sector was active on the same day, contributing to *ST San Sheng's stock price increase, supported by net inflows from major funds [2] - Technical indicators show a bullish trend for the stock, with MACD forming a golden cross and the price breaking through short-term moving average resistance [2]

Core Viewpoint - The company has completed the cancellation of 11.4599 million shares, reducing its total share capital from 911 million to 899 million shares, which aims to enhance shareholder value and long-term investment potential [1][4] Group 1: Share Buyback and Cancellation - The share cancellation was a strategic decision made in October, shifting from an employee stock ownership plan to direct cancellation, reflecting the company's commitment to shareholder interests [1][3] - The company spent approximately 79.9967 million yuan on the repurchase, with an average price of 6.98 yuan per share, which will directly improve key financial metrics such as earnings per share [1][3] Group 2: Business Strategy and Acquisitions - The company has acquired a 20% stake in JunTai Pharmaceutical for 25 million yuan, achieving 100% ownership, which allows for better integration of resources in the pharmaceutical sector [2] - This acquisition aligns with the company's strategy to strengthen its position in the pharmaceutical and chemical industry, laying a solid foundation for long-term growth [2] Group 3: Industry Context and Future Outlook - The Ministry of Industry and Information Technology has set a target for the petrochemical industry to achieve an average annual growth of over 5% from 2025 to 2026, emphasizing supply-side structural reforms [2] - The company is well-positioned to benefit from industry consolidation and policy improvements, particularly in the pharmaceutical CDMO sector, which is expected to gain market share amid industry changes [3][4]

Core Viewpoint - Jiangxi Yuhua Pharmaceutical Co., Ltd., a subsidiary of Jingdezhen Black Cat Group, has been re-evaluated and recognized as a "specialized, refined, distinctive, and innovative" small and medium-sized enterprise in Jiangxi Province due to its strong technical foundation and market performance in the pharmaceutical and chemical industry [1] Group 1: Company Overview - Yuhua Company has evolved from a small chemical synthesis plant to a comprehensive pharmaceutical and fine chemical enterprise, focusing on the production of active pharmaceutical ingredients, pharmaceutical intermediates, organic solvents, and chemical raw materials [1] - In 2018, the company relocated to a new facility in the high-tech zone, equipped with advanced safety, environmental protection, and wastewater treatment facilities that meet strict national environmental and safety standards [1] Group 2: Achievements and Certifications - In March 2022, Yuhua Company received the Certificate of Suitability for European Pharmacopoeia (CEP) for Piracetam from the European Medicines Agency and completed drug registration in Russia [1] - The company has been recognized as a provincial benchmark for water conservation, a provincial "specialized, refined, distinctive, and innovative" small and medium-sized enterprise, and a provincial specialized small giant enterprise, highlighting its core competitiveness in niche markets [1]

Core Viewpoint - The article discusses the economic performance of various cities in China during the first three quarters of 2025, highlighting GDP growth rates and the emergence of new economic powerhouses among both traditional and non-traditional cities [1][2][3]. Group 1: Economic Performance of Major Cities - Beijing, Shanghai, and Shenzhen are leading in GDP growth, supported by high-tech industries, particularly in artificial intelligence and new energy vehicles [2][3]. - Guangzhou's economy is stabilizing with significant improvements in industrial output and foreign trade, which increased by 12.5% [2]. - Ningbo has surpassed Tianjin in GDP, while Qingdao is closing in on Tianjin, indicating a potential shift in economic rankings among northern cities [3]. Group 2: Emerging Cities and Economic Clubs - The number of trillion-yuan GDP cities is expected to increase, with cities like Wenzhou, Xuzhou, and Dalian vying for entry into the trillion-yuan club [11][12]. - Wenzhou has shown consistent GDP growth exceeding 6% for ten consecutive quarters, driven by industrial contributions, particularly in electronics and automotive manufacturing [15]. - Xuzhou is recognized for its engineering machinery industry, benefiting from major domestic and international projects, while Dalian's strengths lie in its port and shipping capabilities [15][16]. Group 3: Non-Capital City Dynamics - The competition for the title of the leading non-capital city in Central and Western China is intensifying, with cities like Luoyang, Xiangyang, and Yichang emerging as contenders [20][21]. - Yichang has the highest GDP growth rate among the top 50 cities, driven by industrial diversification and emerging sectors like lithium batteries and biomedicine [22]. - The success of non-capital cities heavily relies on their industrial base and the development of new industries, as they lack the administrative advantages of capital cities [23][24].